1146 related articles for article (PubMed ID: 21896352)
21. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
22. Global prevailing and emerging pediatric pneumococcal serotypes.
McIntosh ED; Reinert RR
Expert Rev Vaccines; 2011 Jan; 10(1):109-29. PubMed ID: 21162625
[TBL] [Abstract][Full Text] [Related]
23. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
[TBL] [Abstract][Full Text] [Related]
24. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
Gladstone RA; Jefferies JM; Faust SN; Clarke SC
Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
[TBL] [Abstract][Full Text] [Related]
25. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine.
Aguiar SI; Serrano I; Pinto FR; Melo-Cristino J; Ramirez M;
Clin Microbiol Infect; 2008 Sep; 14(9):835-43. PubMed ID: 18844684
[TBL] [Abstract][Full Text] [Related]
26. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
27. [Disribution of Streptococcus pneumoniae serotypes and serogroups among patients with invasive pneumococcal diseases in the Czech Republic in 1996-2003: background data for vaccination strategy].
Motlová J
Epidemiol Mikrobiol Imunol; 2005 Feb; 54(1):3-10. PubMed ID: 15807381
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
[TBL] [Abstract][Full Text] [Related]
29. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Lancet Infect Dis; 2011 Oct; 11(10):760-8. PubMed ID: 21621466
[TBL] [Abstract][Full Text] [Related]
30. Implication of pneumococcal conjugate vaccines to public health: Thailand perspective.
Wongsawat J; Chokephaibulkit K
J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S53-60. PubMed ID: 21294383
[TBL] [Abstract][Full Text] [Related]
31. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3+0 pneumococcal conjugate vaccine schedule.
Wiertsema SP; Kirkham LA; Corscadden KJ; Mowe EN; Bowman JM; Jacoby P; Francis R; Vijayasekaran S; Coates HL; Riley TV; Richmond P
Vaccine; 2011 Jul; 29(32):5163-70. PubMed ID: 21621576
[TBL] [Abstract][Full Text] [Related]
32. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
[TBL] [Abstract][Full Text] [Related]
33. 13-valent pneumococcal conjugate vaccine.
Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
35. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
36. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.
Hicks LA; Harrison LH; Flannery B; Hadler JL; Schaffner W; Craig AS; Jackson D; Thomas A; Beall B; Lynfield R; Reingold A; Farley MM; Whitney CG
J Infect Dis; 2007 Nov; 196(9):1346-54. PubMed ID: 17922399
[TBL] [Abstract][Full Text] [Related]
37. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies.
Sniadack DH; Schwartz B; Lipman H; Bogaerts J; Butler JC; Dagan R; Echaniz-Aviles G; Lloyd-Evans N; Fenoll A; Girgis NI
Pediatr Infect Dis J; 1995 Jun; 14(6):503-10. PubMed ID: 7667055
[TBL] [Abstract][Full Text] [Related]
38. 13-valent pneumococcal conjugate vaccine (PCV13).
Jefferies JM; Macdonald E; Faust SN; Clarke SC
Hum Vaccin; 2011 Oct; 7(10):1012-8. PubMed ID: 21941097
[TBL] [Abstract][Full Text] [Related]
39. Prevention of pneumococcal disease through vaccination.
Gentile A; Bazán V
Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
[TBL] [Abstract][Full Text] [Related]
40. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.
Gruber WC; Scott DA; Emini EA
Ann N Y Acad Sci; 2012 Aug; 1263():15-26. PubMed ID: 22830997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
